pharma · Cerebral adrenoleukodystrophy (cALD) · Adrenoleukodystrophy
Minoryx Therapeutics
Minoryx Therapeutics S.L.
Minoryx Therapeutics S.L is a pharma organization headquartered in EU. Primary therapeutic focus areas include Cerebral adrenoleukodystrophy (cALD), Adrenoleukodystrophy, Rett Syndrome, CEREBRAL X-LINKED ADRENOLEUKODYSTR
ES HQ
2011 Founded
32 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- ES
- Founded
- 2011
- Employees
- 32
- Programs
- 4
- Drugs
- 11
- Patents
- 0
MT-3-01
Phase 3 · small molecule · Cerebral adrenoleukodystrophy (cALD)
MT-3-01 for Cerebral adrenoleukodystrophy (cALD) is a Phase 3 program (small_molecule) at Minoryx Therapeutics S.L. with 1 ClinicalTrials.gov record(s).
Internal code MT-3-01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Minoryx Therapeutics S.L.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Cerebral adrenoleukodystrophy (cALD)
- Status
- active
- Trials
- 1